Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Rigaku Launches New Curved Single Crystal X-ray Diffraction Detector with Smaller Form Factor


Rigaku HyPix-Arc 100°

Rigaku HyPix-Arc 100° Curved Photon Counting X-ray Detector

HyPix-Arc 100° detectors are ideally suited for measuring diffraction from small and poorly diffracting samples due to the extremely low noise characteristics.

Rigaku Corporation is pleased to announce the release of the Rigaku HyPix-Arc 100° curved photon counting (HPC) X-ray detector for single crystal X-ray diffraction applications. The newest addition to the Rigaku HyPix line, the HyPix-Arc 100° detector applies Rigaku’s curved HPC concept to a smaller, more agile form factor. It follows the early success of the HyPix-Arc 150° detector, which demonstrated that curved detectors were not only sensible but also highly desirable. The detector was first announced in the November edition of Crystallography Times, an electronic newsletter published by Rigaku focusing on single crystal X-ray diffraction.

Rigaku adopted the HPC detector technology for its HyPix brand of detectors due to its unique, beneficial characteristics. HPC detectors directly count X-ray photons as they strike the detector and eliminate the need for an intermediate conversion of X-rays to light and subsequent integration of the signal.

The HyPix-Arc 100° detector offers 100° of angular coverage from edge to edge and a 17° larger capture angle compared to a flat detector, delivering enhanced speed for rapid acquisition of complete and redundant data. The curvature minimizes peak distortion by ensuring that, even at short crystal-to-detector distances, diffracted beams are closer to perpendicular than is possible with a flat geometry, which improves data quality, enabling the collecting of more data in a single exposure with less reflection profile distortion. The angular coverage is more than enough to collect complete single crystal diffraction data according to International Union of Crystallography (IUCr) guidelines from a single theta position, even for Cu Kα X-ray wavelength.

HyPix-Arc 100° detectors are ideally suited for measuring diffraction from small and poorly diffracting samples due to the extremely low noise characteristics. Counting can continue as long as needed without the dark current or noise build up seen in other detectors.

High and low angle data are measured at the same time, under the same conditions, for better scaling, faster data collection and reduced dose time. The physical size of a detector face is not an indicator of how much data can be measured, as it also depends on the crystal-to-detector distance, relative pixel size, and point spread function or lack thereof.

HPC detectors can be positioned much closer to the sample, leading to a larger apparent aperture size. When the aperture is curved, it creates an even larger capture angle in the horizontal direction and far surpasses the flat detectors of alternative technologies. Another advantage is the direct detection found in the HyPix-Arc 100° detector, resulting in reflections that are sharper and more easily resolved.

The HyPix-Arc 100° detector is available as an option on the popular Rigaku XtaLAB Synergy line of X-ray diffractometers for single crystal X-ray diffraction analysis. More information about crystallography systems and detectors rom Rigaku is available at https://www.rigaku.com/products/crystallography.

About Rigaku

Since its inception in Japan in 1951, Rigaku has been at the forefront of analytical and industrial instrumentation technology. Rigaku and its subsidiaries form a global group focused on general-purpose analytical instrumentation and the life sciences. With hundreds of major innovations to their credit, Rigaku companies are world leaders in X-ray spectrometry, diffraction, and optics, as well as small molecule and protein crystallography and semiconductor metrology. Today, Rigaku employs over 1,400 people in the manufacturing and support of its analytical equipment, which is used in more than 90 countries around the world supporting research, development, and quality assurance activities. Throughout the world, Rigaku continuously promotes partnerships, dialog, and innovation within the global scientific and industrial communities.

For further information, contact:

Paul Swepston, Ph.D.,

SVP of Global Single Crystal Sales and Marketing

Rigaku Corporation

Paul.Swepston@rigaku.com

Share article on social media or email:

Clarion Safety Systems Launches New Product Safety and Risk Assessment Platform, Clarion Safety Assessment


Clarion Safety Assessment is a new platform offering machine risk assessments, warnings and label reviews and product safety consulting,

Clarion Safety’s main focus has been on product warnings and instructions. Now, we’re expanding that reach to answer the wider needs of our clients, helping to identify, remedy and prevent comprehensive product safety and compliance issues.

Clarion Safety Systems, a leading manufacturer of safety labels, signs and tags, has expanded its portfolio with a new product safety and risk assessment platform, Clarion Safety Assessment. Available at its sister website, http://www.clarionsafetyassessment.com, services now available for equipment manufacturers include machine risk assessments, warnings and label reviews and product safety consulting.

“Safety and liability are a concern for nearly every equipment and machinery manufacturer. There are multiple aspects involved in bringing safe, compliant products into the marketplace – and each needs to be assessed and handled effectively,” says Ron Crawford, CEO of Clarion Safety. “Until recently, Clarion Safety’s main focus has been on product warnings and instructions. Now, we’re expanding that reach to answer the wider needs of our clients, helping to identify, remedy and prevent comprehensive product safety and compliance issues.”

Clarion Safety has a longstanding, 30 year history of collaborating with customers to implement best practices in relation to a broad range of product safety standards with the goal of maximizing safety and reducing risk. Clarion Safety Assessment will be driven by that same commitment to excellence, punctuated by a track record of working with over 15,000 companies without a single Clarion Safety customer ever facing warnings-based allegations.

“Our team not only has a thorough understanding of the ANSI and ISO standards for product safety and risk – we’re involved at the leadership level on many of the key national and international committees. We put that knowledge into practice for each of our clients, guiding them through their specific challenges.”

Clarion Safety Assessment Services

Clarion Safety Assessment provides full-service product safety and liability prevention capabilities, offered through a team of experts, each with specific areas of proficiency.

Services include:

  • Machine risk assessment: Risk assessments are a powerful tool in identifying and reducing hazards – making them the foundation of a product safety program. The Clarion Safety Assessment team helps ensure the risk assessment follows a formal method based on the needs at hand and today’s best practices. The end result: effective processes and outcomes are established in line with a comprehensive safety strategy.
  • Warnings and label reviews: Communicating risk through warnings is a critical component of risk reduction, especially when it’s not practical to design out or guard against a particular hazard. However, there’s a reason that “failure to warn” and “inadequate warnings” continue to top today’s product liability allegations: creating effective on-product warnings isn’t always easy. In this personalized label or label program evaluation, the Clarion Safety Assessment team reviews the latest standards and best practices and makes tangible recommendations.
  • Consulting: There are many different elements in an effective product safety program. Whether a company is looking to put their program to the test or has known issues but are unsure where to begin, Clarion Safety’s consulting solution is an effective starting point. Examples of types of consulting offered include product safety/liability strategy, specifying safety requirements like machine guarding, best practices for product safety manuals, and litigation support.


More information can be found at http://www.clarionsafetyassessment.com.

ABOUT CLARION SAFETY SYSTEMS

Clarion Safety Systems, LLC, is the leading designer and manufacturer of visual safety solutions that help customers in more than 180 industries worldwide to make their products and premises safer. Clarion Safety offers a full range of standard and custom products including machinery safety labels, environmental and facility safety signs, pipe and valve identification markings, lockout/tagout products, and safety-grade photoluminescent egress path-marking escape systems. Founded in 1990, the company continues to play a leading role in the development and writing of international and national standards for safety signs, labels, and markings. Clarion Safety is headquartered at 190 Old Milford Road in Milford, PA, 18337, and online at http://www.clarionsafety.com.

Share article on social media or email:

Enlighten MD Joins Exclusive Haute Beauty Network Representing The Medspa Category


Enlighten MD is home to renowned endocrinologist Dr. David Feinstein who serves as the medical director, while the tenured team brings with them decades of experience.

Enlighten MD is known as the premier destination in Dallas for beauty and aesthetics with an award-winning selection of services that are combined with highly customized treatment plans to produce what you want… Results. The team is comprised of highly educated professionals who are true problem solvers. They focus on creating solutions to address your concerns while monitoring your progress every step of the way. Proud to be located in the heart of Preston Hollow, they pride themselves on providing discreet service within their state-of-the-art facility.

Enlighten MD is home to renowned endocrinologist Dr. David Feinstein who serves as the medical director, while the tenured team brings with them decades of experience. As a brand, their philosophy is simple, they spare no attention to detail. From the initial client consultation to the personalized treatment plans they create. Enlighten MD Strives to provide best in class service, care, and results, always and in all ways.

Behind the Brand

As a woman who has always valued being pampered and investing in self-care, founder Kari Feinstein is passionate about delivering the best experience possible for each and every client. Kari has invested over 15 years into developing the Enlighten Experience which custom tailors treatment plans for each individual. One size fits all? Kari doesn’t believe in it. Which is why her patients see results.

Designed for every type of beautiful, the Enlighten Experience is focused on simplifying client’s lives by providing comprehensive medspa services, beauty treatments, styling, and wardrobe options at the onsite clothing boutique, Enlighten Living, and now a full-service hair salon, Enlighten Salon. Spend the day with the team to recharge, rejuvenate, and indulge a little.

Learn more about Enlighten MD by visiting: https://hauteliving.com/hautebeauty/member/enlighten-md/

ABOUT HAUTE BEAUTY NETWORK:

Haute Beauty is affiliated with the luxury lifestyle publication Haute Living. As a section of Haute Living magazine, Haute Beauty covers the latest advancements in beauty and wellness, providing readers with expert advice on aesthetic and reconstructive treatments through its network of acclaimed doctors and beauty experts.

For more about Haute Beauty, visit https://hauteliving.com/hautebeauty/

Share article on social media or email:

Careaga Plastic Surgery Continues Partnership With Exclusive Haute Beauty Network


Dr. Careaga has been voted among the top five plastic surgeons in Florida by his patients and peers for five years in a row.

DANIEL CAREAGA, M.D.

DOUBLE BOARD CERTIFIED PLASTIC SURGEON

Dr. Daniel Careaga is an award-winning plastic surgeon who specializes in a range of body, face, and breast procedures. By utilizing his extensive experience in all these fields, Dr. Careaga has gained a reputation for being a meticulous plastic surgeon with a powerful practice: Careaga Plastic Surgery.

Dr. Careaga holds a rare double board certification in plastic surgery. With the experience of over 8,000 successful operations performed, Dr. Careaga knows beauty and what his patients want.

“I don’t believe in cookie-cutter surgery. Each patient has a different body and face style and different goals in mind. By actively involving them in the process, I can consistently deliver the best possible result.” -Daniel Careaga, M.D.

PAUL DURAND, M.D.

Dr. Paul D. Durand is a Cleveland Clinic-trained plastic and reconstructive surgeon specializing in procedures of the face and body. Born in Miami and raised in Peru, he obtained all his medical education and training in the United States. Dr. Durand has maintained close ties to his hometown of Lima, which inspired a passion for international mission work in South America, completing his seventh cleft surgery mission trip last year.

Dr. Durand completed a fellowship in Aesthetic Plastic Surgery at the Dallas Plastic Surgery Institute, considered the top program in the nation for cosmetic surgery. Since then, Dr. Durand has gained extensive recognition in both plastic and reconstructive surgery and has presented and published on numerous topics, including invitations to lecture and perform live surgical demonstrations in Latin America and Asia.

Dr. Durand is licensed to practice in the state of Florida, Texas, and Ohio.

REANA MYERS, MMS, PA-C

Reana Myers is a board-certified physician assistant specializing in aesthetic medicine. She was born in Tirana, Albania, and moved to the United States when she was young. After obtaining a master’s degree in medical science from Nova Southeastern University in 2007, Reana started her career in cardiovascular medicine before transitioning into the field of plastic surgery. She has over 10 years of experience in the medical field. Reana’s professional interests include injectables such as Botox and Dysport, as well as facial fillers such as Juvederm, Voluma, Restylane, Sculptra, Radiesse, etc. She is skilled and knowledgeable in various other non-surgical treatments such as CO2, fractional, IPL, SculpSure lasers, micro-needling, PRP, sclerotherapy, and weight loss. Reana is board certified by the National Commission on Certification of Physician Assistants and is licensed to practice and prescribe in the State of Florida.

“There is beauty in everyone. That is why my goal is to enhance your beauty naturally and safely.”  – Reana Myers, PA-C, MMS

WHY CHOOSE CAREAGA PLASTIC SURGERY?

Careaga Plastic Surgery is a state-of-the-art facility that has gained a reputation for being a phenomenal plastic surgery and medspa practice that utilizes the latest and most innovative technology in the industry. This modern facility specializes in a variety of procedures such as breast augmentation, breast lift, body contouring, tummy tuck, and non-surgical procedures, making Careaga Plastic Surgery the best place to start your beauty journey.

Careaga Plastic Surgery, where safety meets luxury, holds the coveted Gold Seal from the Joint Commission (JCAHO). Dr. Careaga has been voted among the top five plastic surgeons in Florida by his patients and peers for five years in a row. Careaga Plastic Surgery is where patients go to be their own masterpiece!

Learn more about Careaga Plastic Surgery by visiting: https://hauteliving.com/hautebeauty/member/careaga-plastic-surgery/

ABOUT HAUTE BEAUTY NETWORK:

Haute Beauty is affiliated with the luxury lifestyle publication Haute Living. As a section of Haute Living magazine, Haute Beauty covers the latest advancements in beauty and wellness, providing readers with expert advice on aesthetic and reconstructive treatments through its network of acclaimed doctors and beauty experts.

For more about Haute Beauty, visit https://hauteliving.com/hautebeauty/

Share article on social media or email:

Wildfire Orphans, Captain Cal & Adopted Sisters, to Depart Soon for New Home at the Columbus Zoo and Aquarium


Photos shows two other rescued cubs, both females, that are now bonded with Captain Cal on far right

We’re grateful and beyond happy that Captain Cal has made such an amazing recovery and now has a family with the two females.

Named “Captain Cal” by the Cal Fire firefighters who found him limping down a burned-out road in Redding on September 30, 2020, the severely burned orphaned mountain lion cub is now fully recovered, 47 days after he was first rushed to Oakland Zoo’s veterinary hospital by the California Department of Fish & Wildlife (CDFW). With surgery, antibiotics, supportive fluids, pain medication, hand feedings, daily bandage changes, and round-the-clock care, he is ready to make the journey to his new home at the Columbus Zoo and Aquarium in Ohio sometime within the coming weeks. Captain Cal will be joined by two (unrelated to him) female cubs also orphaned by the California wildfires and rehabilitated by Oakland Zoo’s veterinary team.

In the coming weeks, the cubs will travel together on a flight from Oakland to Indianapolis, Indiana, accompanied by Oakland Zoo Zoological Manager, Angela Gibson, and the Columbus Zoo’s Vice President of Animal Health, Dr. Randy Junge, to help ensure that the cubs arrive safely. In Indianapolis, they will be met by additional members of the Columbus Zoo’s Animal Care team who oversee the Zoo’s North America region where the cubs will be residing. This team will also be a part of escorting the cubs during the last leg of their journey as they drive to the cubs’ new home at the Columbus Zoo and help get the cubs settled in comfortably.

Though typically solitary, recent research has shown that mountain lions are more social than scientists previously thought. After a mandatory quarantine period, and once the cubs are medically cleared, the Columbus Zoo team hopes to eventually introduce the cubs to female mountain lion, Jessie. At almost 17 years old, Jessie has surpassed the median life expectancy of 16 years for mountain lions in human care at facilities accredited by the Association of Zoos and Aquariums (AZA). While she is now nearly blind, she is still in good health overall. The Columbus Zoo’s Animal Care team notes that she has a sweet disposition toward other mountain lions—she was very close to her brother, Billy, with whom she was rescued as part of a wildlife confiscation in 2004. Billy passed away in early 2020, and the team hopes to provide Jessie with the opportunity to form a bond with the cubs in the future.

As another way to highlight the important collaboration of Oakland Zoo and the Columbus Zoo to help wildlife in need, Oakland Zoo staff has offered the Columbus Zoo team the chance to name the female cubs. The Columbus Zoo will announce the cubs’ names in the coming weeks.

“Even with the cubs’ tragic beginning, their story is actually one of survival and hope. We are proud to work with our friends at Oakland Zoo, whose expertise has given these cubs another chance. We remain committed to the cubs’ care, and we will continue to share their important story with others as we work together to protect the future of wildlife and wild places,” said Columbus Zoo and Aquarium President/CEO Tom Stalf.

Like Captain Cal, his two new “sister” cubs were rescued by firefighters. The female cubs were orphaned by the August Complex fire, and while they did not suffer from burns like Captain Cal, the sisters were estimated to be only 3-4 weeks old when they arrived at Oakland Zoo’s Vet Hospital on October 9, 2020—10 days after Captain Cal’s arrival.

Captain Cal was 4-6 weeks of age and weighed only 3.75 pounds when he arrived at Oakland Zoo. His most serious injuries were the severe burns he sustained to the pads of his paws, which made him unable to walk. Director of Oakland Zoo’s Veterinary Hospital Dr. Alex Herman, along with her staff and an expert wound specialist from UC Davis Veterinary Medicine Teaching Hospital, performed extensive surgery to remove the pads so they could be allowed to regrow and heal. Daily bandage changes and advanced wound care procedures were successful and he is now fully healed and weighs a healthy 15 pounds. X-rays and an echocardiogram were also conducted by a Board-certified radiologist to ensure his heart and lungs were/are healthy.

A webpage about Captain Cal’s recovery journey was created on Oakland Zoo’s website in early November to keep the public updated on his progress as a result of the outpouring of interest. As Captain Cal underwent daily treatment, Oakland Zoo vet and animal care staff were eager to provide Captain Cal the companionship of the female cubs, but patience was required so that Captain Cal could recover enough so that the introductions to one other could safely happen.

That day came on October 28, when the cubs were introduced. Their bonding with one another was immediate, and the cubs have been together ever since—playing, cuddling and sleeping together.

Due to the widespread media coverage that helped raise awareness about their important story, many AZA-accredited zoos and other facilities were aware that the cubs needed to be placed and reached out to Oakland Zoo to offer a home for the three cubs. The Columbus Zoo was ultimately selected due to their excellence in animal care, welfare and previous experience in assisting rescued North American animals, including black bears, brown bears, moose and mountain lions.

Dr. Herman and her team at Oakland Zoo have conducted thorough final health exams on all three cubs in preparation for their departure. She and her vet team are ready to take in more wildfire victims as needed, as the effects of global warming make evident that fire threats are increasing yearly. As more wildlife victims are in need of care and rehabilitation, facilities with resources and expertise available to care for these animals are becoming scarce. Collaborating with CDFW and UC Davis School of Veterinary Medicine on the newly formed “Wildfire Relief Network” for burned wildlife was created in October 2020 as a response to the growing problem.

“We’re grateful and beyond happy that Captain Cal has made such an amazing recovery and now has a family with the two females. These cubs’ poignant faces have made an impact on so many, and helped raise awareness around the issue of global warming and the environment we – and these animals – live in. We’re fully committed to continue taking in burned wildlife that need our help, and hopefully, one day that need will no longer exist,” said Dr. Herman.

In their native range, mountain lion cubs stay with their mothers until they are around two years of age in order to learn the skills to survive on their own. Because these cubs were orphaned at such a young age, they would be unable to learn how to survive in the wild.

Fifteen mountain lion orphans have been brought to Oakland Zoo since 2017. Aside from wildfires, mountain lions are facing numerous threats in California—often struck by cars and illegally poached. These factors culminate in the human-wildlife conflict, putting them at odds with humans in encroaching urban areas and developments. Oakland Zoo partners with conservation organizations like the Mountain Lion Foundation and the Bay Area Puma Project to educate the public on the issue and help conserve the species in the wild.

Oakland Zoo helped found BACAT (Bay Area Cougar Action Team) in 2013, an alliance with the Bay Area Puma Project and the Mountain Lion Foundation, to help support the CDFW to save mountain lions caught in the human-wildlife conflict.

Contact:

Erin Harrison

Oakland Zoo

eharrison@oaklandzoo.org

Office: 510-632-9525 ext. 120

Cell: 415-601-1619

Isabella Linares

Oakland Zoo

ilinares@oaklandzoo.org

Office: 510-632-9525 ext. 239

Cell: 650-776-9589

Nicolle Gómez Racey

Columbus Zoo and Aquarium

nicolle.racey@columbuszoo.org

Office: 614-645-3411

Cell: 614-843-3611

Jen Fields

Columbus Zoo and Aquarium

jen.fields@columbuszoo.org

Office: 614-645-3579

Cell: 614-595-8989

ABOUT OAKLAND ZOO AND THE CONSERVATION SOCIETY OF CALIFORNIA

Oakland Zoo, home to more than 750 native and exotic animals, is managed by the Conservation Society of California (CSC); a non-profit organization leading an informed and inspired community to take action for wildlife locally and globally. With over 25 conservation partners and projects worldwide, the CSC is committed to conservation-based education and saving species and their habitats in the wild. Oakland Zoo is dedicated to the humane treatment of animals and is accredited by the Association of Zoos and Aquariums (AZA), the national organization that sets the highest standards for animal welfare for zoos and aquariums.

ABOUT THE COLUMBUS ZOO AND AQUARIUM

Home to more than 10,000 animals representing over 600 species from around the globe, the Columbus Zoo and Aquarium leads and inspires by connecting people and wildlife. The Zoo complex is a recreational and education destination that includes the 22-acre Zoombezi Bay water park and 18-hole Safari Golf Course. The Columbus Zoo and Aquarium also manages The Wilds, a 10,000-acre conservation center and safari park located in southeastern Ohio. The Zoo is a regional attraction with global impact, annually contributing privately raised funds to support conservation projects worldwide. A 501(c)(3) nonprofit organization, the Columbus Zoo has earned Charity Navigator’s prestigious 4-star rating.

Barth Syndrome Foundation urgently appeals to FDA and Stealth BioTherapeutics to provide access to potential therapy


“Considering the significant loss of life within our community and that there are no other FDA-approved treatment options, it is absolutely critical that the agency truly incorporate the patient voice in their decision-making process.”

Barth Syndrome Foundation (BSF) today announced a series of advocacy initiatives directed toward U.S. Food and Drug Administration (FDA) and Stealth BioTherapeutics requesting immediate access to the investigational drug elamipretide. Specifically, BSF and the Barth syndrome community are petitioning the drug developer to submit a new drug application (NDA) to FDA requesting approval of the investigational compound elamipretide in people with the ultra-rare and life-threatening disease Barth syndrome. “In the last 13 months alone, seven people with Barth syndrome in our community have died,” says Emily Milligan, BSF Executive Director. “This represents nearly 3% of our worldwide living population. Every person with Barth syndrome deserves a chance.”

People with Barth syndrome who were enrolled in the elamipretide clinical trial and open-label extension period over the last three years showed positive changes in functional assessments such as fatigue, muscle strength, and endurance as well as improvements in some cardiac measures. One participant in the clinical trial stated that “I HAD Barth syndrome as I don’t live with the symptoms of Barth syndrome anymore.” Another described the benefit he experienced as life-changing; “I have energy to live now. I feel as if I had never understood before what it meant to live.”

Given the life-threatening nature of the disease and acceptable safety profile of elamipretide, the community is appealing to FDA to forgo the need for additional pre-approval studies and provide immediate access. “Considering the significant loss of life within our community and that there are no other FDA-approved treatment options, it is absolutely critical that the agency truly incorporate the patient voice in their decision-making process,” said Milligan. “We are asking FDA and Stealth BioTherapeutics to hear our voice and work together to provide access to elamipretide to people with Barth syndrome as soon as possible.”

Among BSF’s efforts is a petition signed by over 4200 supporters, accompanied by more than 730 written testimonials. This petition calls for “Stealth and FDA to address this issue with urgency by submitting and approving an NDA for elamipretide in Barth syndrome based on existing evidence from clicnial trials.” We also are aware that a letter from 26 Barth syndrome clinical specialists and key healthcare providers has been sent to the FDA advocating for the treatment. In part, the letter states “As physicians, we view the potential benefit afforded by elamipretide relative to the favorable safety profile exhibited to date as supporting a decision to make this drug immediately available to patients and prescribing physicians.”

FDA has repeatedly signaled the importance of incorporating the patient voice in drug development, including passage of the 21st Century Cures Act. This act requires sponsors to include, and FDA to consider, the patient perspective. Consequently, BSF has been actively engaging with FDA to raise awareness of the patient perspective in Barth syndrome in conjunction with the development of elamipretide over the last three years. Activities by BSF have included coordination of an externally led patient-focused drug development meeting in 2018, publication of the subsequent The Voice of the Patient: Barth Syndrome report and additional listening sessions with the community in 2019. Ongoing efforts in 2020 ensure that community members are informed, educated and have ample opportunity to share their experiences on living with Barth syndrome and their perspectives on risk-benefit considerations for potential therapies.

Disclosure: BSF has received sponsorship support for advocacy, clinical education and family-centered support programs from Stealth BioTherapeutics.

ABOUT BARTH SYNDROME FOUNDATION (BSF)

Barth Syndrome Foundation (barthsyndrome.org) is the only global network of families, healthcare providers, and researchers solely driven by the mission to save lives through education, advances in treatment and finding a cure for Barth syndrome. BSF has funded nearly $5.6M USD since 2002 and catalyzed over $31.7M USD in funding from other agencies to advance global scientific discoveries to end the suffering and loss of life from Barth syndrome. Additionally, BSF provides a lifeline to families and individuals living with Barth syndrome around the world, offering individualized support, educational conferences, a robust patient registry and collaborations with specialist healthcare providers to define standards of care, treatment and rapid diagnosis.

ABOUT BARTH SYNDROME

Barth syndrome is a rare, life-threatening, genetic mitochondrial disorder primarily affecting males. Affected individuals may suffer from heart failure, muscle weakness, and infection (caused by neutropenia). Additional characteristics of the syndrome commonly include growth delay, impaired lipid metabolism, extreme fatigue and cardiolipin deficiency. In some individuals affected by Barth syndrome, the symptoms can be very severe, resulting in heart transplantation, potentially lethal infections, and death.

Share article on social media or email:

What Drives Painful Bone Metastasis in Prostate Cancer, and Can it Be Prevented?


Dr. Subhamoy Dasgupta and the Roswell Park Cell Stress Biology team examined bone metastases in individuals with advanced prostate cancer.

“In this study, we provide evidence that prostate tumor cells alter their mitochondrial metabolism to increase synthesis of fats, which serve as a sort of food source enabling the prostate cells to take root and survive in a new location.”

– People with prostate cancer often face painful bone metastases

  • Study identifies enzyme vital to the metastatic growth of prostate cancer cells
  • Findings reveal potential strategy for treating bone-metastatic prostate cancer

While prostate cancer originates within the prostate, metastasis, or the spread of a tumor from the site of origin to other organs, remains a leading cause of death among people with the disease. Prostate tumors can metastasize to a number of different organs, including the liver, lymph nodes and bone.

People with advanced prostate cancer often develop bone metastases — lesions of prostate cancer growing on distant bones — that are very painful and difficult to treat. Given the significant differences between the microenvironments surrounding the bone and prostate, a team from Roswell Park Comprehensive Cancer Center set out to learn more about how prostate tumors survive and grow in the bone.

Led by Subhamoy Dasgupta, PhD, Assistant Professor of Oncology in Roswell Park’s Department of Cell Stress Biology, the team determined that prostate tumors change their metabolism to produce more fats, which helps them survive within the bones. The team’s findings have been published online in Cancer Research, a journal of the American Association for Cancer Research.

Data from this study suggest that a mitochondrial enzyme called aconitase plays a key role in the development and viability of prostate cancer cells. The Roswell Park research team discovered that prostate tumors are able to alter their metabolism and produce additional fats by stimulating this enzyme.

“There’s a fundamental gap in knowledge regarding how prostate tumor cells survive inside the bone,” explains Dr. Dasgupta, senior author of the new work. “In this study, we provide evidence that prostate tumor cells alter their mitochondrial metabolism to increase synthesis of fats, which serve as a sort of food source enabling the prostate cells to take root and survive in a new location.”

The team reports that activation of aconitase is enabled by suppressing a deacetylase enzyme named sirtuin-3, or SIRT3, resulting in increased lipid synthesis.

Previous studies have associated increased expression of another protein, SRC-2, with aggressive prostate cancer. In the current study, Dr. Dasgupta and colleagues determined that patients with high SRC-2 in their tumors simultaneously saw low expression of SIRT3, helping those aggressive tumors to spread to new sites. Through their preclinical work in the lab, the investigators showed that the loss of SRC-2 significantly reduced metastatic growth of prostate cancer cells in the bone microenvironment.

The team’s findings highlight the importance of mitochondrial metabolic adaptation in the growth of advanced bone metastatic prostate cancer, and suggest that blocking SRC-2 in order to enhance SIRT3 expression may be a viable treatment strategy.

“This is an early-stage discovery identifying potential pathways that could be targeted to block prostate tumor growth inside the bone,” notes Dr. Dasgupta. “We’ve begun additional work to investigate the clinical benefits of our research findings and identify particular drugs or new agents that could block this pathway.”

Abhisha Sawant Dessai, a predoctoral trainee, and Mayrel Palestino Dominguez, PhD, a Postdoctoral Fellow, both from Dr. Dasgupta’s lab team, are co-first authors on the paper.

This work was supported by grants from the National Cancer Institute (project numbers K22CA207578, P30CA016056 and DP2CA260421, the NIH Director’s New Innovator Award) and Department of Defense (award number W81XWH-16-1-0297, and by donations to Roswell Park.

For an online version of this release, please visit: https://www.roswellpark.org/newsroom/202011-what-drives-painful-bone-metastasis-prostate-cancer-can-it-be-prevented

Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at http://www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.

Share article on social media or email:

PALAZZO Advises Jarrard Phillips Cate & Hancock on its Sale to The Chartis Group


Jarrard Tombstone

PALAZZO is pleased to announce it has served as exclusive financial advisor to Jarrard Phillips Cate & Hancock (“Jarrard”), a Nashville-based strategic communications and change management firm serving the healthcare industry, on its sale to The Chartis Group (“Chartis”), a leading healthcare advisory and analytics firm and a portfolio company of Audax Private Equity.

Founded in 2006, award-winning Jarrard ranks among the top 10 healthcare communications firms in the nation. Specializing in areas such as issue navigation, transformation adoption, change management, strategic positioning, and M&A, Jarrard has served more than 500 healthcare provider clients.

Jarrard joins Chartis at a time of great promise and challenge in the nation’s healthcare delivery landscape. U.S. hospitals, health systems, and other providers are confronted with dynamic operational, clinical, and financial challenges while simultaneously being presented with unlimited opportunities for disruption and innovation. In both cases, organizations are facing the need to evolve and continue to grow and transform – which requires not only new strategic, clinical, digital, and operating models – but also the ability to ensure their effective implementation and adoption. To that end, Jarrard brings great complementary strengths to Chartis.

“The power of what our two organizations can do together to help clients fully achieve their strategic and operational objectives could not be greater,” said Ken Graboys, CEO of The Chartis Group. “We believe successful, sustainable transformation requires effective change management and communications. By partnering with Jarrard, we can more effectively deliver results for our clients and the healthcare industry at large.”

“We are combining the power of effective communications with the exceptional strategic, financial, technological, and operational expertise of Chartis,” said David Jarrard, CEO of Jarrard. “We are bringing together the art and the science of change to a rapidly-evolving industry and in service to a mission – shared by both organizations – to work to make healthcare better.”

The acquisition of Jarrard furthers Chartis’ commitment to providing U.S. healthcare providers best-in-class advisory capabilities. Under the partnership, like other sister companies, Jarrard retains its brand, culture, leadership, and approach to client service, while being augmented by the expertise and resources of Chartis.

Matt Hasson, Managing Director of PALAZZO, remarked on the transaction, “Jarrard is among the best in the business when it comes to advising healthcare providers on important strategic internal/external communications and change management initiatives. Inasmuch as the Jarrard and Chartis offerings are highly complementary, the businesses are also very much aligned with respect to their overarching missions of helping healthcare provider clients navigate the complexities of an ever-changing healthcare environment. On behalf of PALAZZO, it has been a pleasure and a privilege to work with the Jarrard team on this successful transaction, and we wish them all the best in this exciting new partnership with Chartis.”

On working with PALAZZO, David Jarrard expressed, “We needed expert advisors who we could trust to not only guide us through the transaction, but also to translate the intricacies of the process so we could make thoughtful, informed, confident decisions at every milestone. The PALZZO team were valuable partners to us in what was easily one of the most important decisions in the life of our firm.”

Terms of the transaction were not disclosed. Under the agreement, Jarrard will continue to operate with its existing leadership and staff as a wholly owned subsidiary of Chartis.

About PALAZZO

PALAZZO is a New York City-based investment bank that provides M&A advisory, capital raising, and strategic advisory services to entrepreneurs/founders, private equity firms, and strategic acquirers in the marketing services, consulting services, media, and technology sectors. Founded in 2009, PALAZZO has played an integral role in industry-defining transactions, becoming the leading investment bank in the sectors it covers. http://www.palazzonyc.com

Share article on social media or email:

Germinator Mobile Sanitizing and Disinfecting Opens First Alabama Location


Photo of Paul Orton, owner of Germinator Huntsville.

Germinator Huntsville will be owned and operated by Paul Orton.

We’re looking forward to the opening of our first Alabama location. Paul is a leader by nature and was the perfect choice to spearhead our launch in this new market. – said Jeff Gill, Founder and CEO of Germinator.

Germinator Mobile Sanitizing and Disinfecting is continuing its rapid expansion across the country, opening its newest location in the Southeastern United States. The company is proud to announce it has opened its doors in Huntsville, Alabama and will offer high-quality sanitizing and disinfecting services to businesses and residents throughout Madison County.

Germinator Huntsville will be owned and operated by Paul Orton. An educator for over 20 years, the current pandemic led him to open a Germinator franchise in order to provide the community with effective sanitizing and disinfecting services. Germinator has developed a patent-pending process that provides a new generation of microbial protection for both commercial and residential establishments.

“On March 13, with coronavirus on the rise, I was cleaning my classroom after school with a can of disinfectant and was immediately struck by its strong, chemical odor,” said Orton. “I wondered to myself whether or not these products were actually safe, and I discovered that some of the ingredients used in disinfectants can contribute to asthma, dermatitis and other health problems. I wanted to provide the community with a better option for sanitizing and disinfecting, which led me to discover Germinator. Germinator’s HOCl sanitizing and disinfecting solution does not use harsh chemicals or fumes.”

Germinator’s patent-pending methodology is the most unique and cost-effective means of providing enhanced antimicrobial protection for businesses and residences. The company first tests surfaces for ATP using a luminometer to detect light that can come from cellular activity. This measurement immediately provides the level of clean on a surface.

The next step is the application of Germinator’s Genesis surface treatment. Genesis is a one-step cleaner and broad-spectrum sanitizer and disinfectant treatment that harnesses the power of hypochlorous acid (HOCl). Derived from naturally occurring minerals, Genesis not only eliminates odors at their source, but kills a wide range of bacteria including Staphylococcus aureus, MRSA, Salmonella enterica and Pseudomonas aeruginosa, and viruses including norovirus, rotavirus and adenovirus on hard, non-porous, environmental surfaces. It meets the Association of Official Agricultural Chemists (AOAC) germicidal spray standards for Hospital Grade Disinfection and is on the EPA’s N List of products determined to meet the criteria for use against SARS-CoV-2, the virus that causes COVID-19. As a result, this treatment will eliminate bacteria and viruses that may reside in your environment without the use of harsh chemicals or fumes.

Following Genesis, Germinator applies its Shield, a water-based quaternary ammonium compound that imparts a durable bacteriostatic finish. It is EPA-registered as effective against mold, mildew, algae and odor-causing bacteria. This application creates an invisible barrier that combats deterioration and discoloration and promotes freshness for up to three months.

The Genesis and Shield products are applied by using an electrostatic sprayer, which is the most efficient and effective means of delivering the products to the intended application sites. After Germinator’s surface treatment and protectant services, the company retests ATP levels to ensure the surfaces have achieved the intended results.

Germinator was founded by Jeff Gill in 2015 with the vision of providing an effective method of proper sanitizing and disinfecting for businesses and households. The company continues to rapidly expand across the United States.

“We’re looking forward to the opening of our first Alabama location,” said Gill. “Paul is a leader by nature and was the perfect choice to spearhead our launch in this new market. He’s led generations of students for over 20 years throughout Alabama, Texas, Tennessee and even across the globe. Now, he is leading the charge of providing Madison County with an effective method for proper sanitization and disinfection.”

Upholding the highest standards of sanitization and disinfection, Germinator makes claims that are scientifically supported and within EPA regulations. The company’s research and process are validated by the Germinator Scientific Advisory Board. The board is made up of key leaders such as Dr. Roscoe M. Moore, Jr. —who was an Assistant to the United States Surgeon General for five administrations; Dr. Harold Smith, who has extensive expertise in cell biology, molecular biology and biochemistry, along with decades of experience leading sponsored research on infectious diseases for the National Institutes of Health (NIH); Dr. David Miller, the Protocol Chair of University of Rochester Center for AIDS Research Community Advisory Board; and Chad S. Johnson, Esq., a Harvard-trained corporate, legislative, and regulatory attorney with significant experience in advising health and biotechnology companies.

“During these unprecedented times, the need to focus on sterilizing agents within our country’s airports, public spaces and offices in order to help decrease the spread of viral pathogens such as coronavirus is essential,” states Dr. Moore. “I am extremely happy to be a part of the Germinator team and lend my expertise in public health and regulatory affairs to what I feel is an immense asset to the containment effort.”

With Germinator, society can now have greater peace of mind and the freedom to live or work in a sanitized and disinfected environment. Businesses and residents in Alabama can learn more by visiting https://www.germinatorhuntsville.com/ or calling (256) 272-9000.

Share article on social media or email:

Premium seafood from Korea with “K-SEAFOOD GLOBAL WEEKS” is back in the U.S.


Premium Seafood from Korea

The launch in 2017 of the Korean Fishery’s national brand, K-FISH, aimed to promote the quality of Korean seafood and enhance its global competitiveness. Each year since then, the Korean Fishery office has held two-week-long promotions in many countries entitled “K-Seafood Global Weeks.” This year’s more extensive efforts have expanded to include B2C (business to consumers) by also introducing Korean seafood products to consumers online as well as offline. These special showcases are currently running in the U.S., Japan, Philippines, Malaysia, Indonesia, and other countries at the same time.

These events introduce K-FISH seafood products and stress the clean ecological environment for its production, their strict brand usage guidelines, and its rigorous quality management. Their 14 Korean seafood products available for export are: Gim (Laver Seaweed), Miyok (Sea Mustard), Oysters, Abalone, Sea Cucumbers, Fish Cake, Red Snow Crab, Seasoned Squid, Conger Eel, Flatfish, Tuna, Baby Calms, Roes and Mackerel.

These showcases are open to public.

You can also visit our website at http://www.kfish.co.kr & http://www.kseafoodusa.com

About K-FISH

K-FISH is the famous Korean Fishery national export brand that offers premium seafood for global seafood lovers. Based on their clean seas, their advanced management, and their stringent tests, K-FISH’s products are of the best quality and very safe. Now you can purchase their wonderful seafood in U.S. markets. Every product is a precious gift from their pure seas and matches their meticulous procedures.

All of their delicious seafood is from Korea!

Share article on social media or email: